Welcome!

News Feed Item

InterMune® Announces Support for First Ever European Patient Charter on Idiopathic Pulmonary Fibrosis (IPF)

MUTTENZ, Switzerland, February 28, 2014 /PRNewswire/ --

To mark international Rare Disease Day, InterMune today announces its support for the development of a European Patient Charter for people with idiopathic pulmonary fibrosis (IPF).

     (Logo: http://photos.prnewswire.com/prnh/20140228/672014 )

IPF is an irreversible, progressive and ultimately fatal fibrotic interstitial lung disease[i],[ii]. IPF has a projected survival rate of only 20-40% after five years,[i],[ii] making it more rapidly lethal than many cancers [iii],[iv]. The disease causes scarring of the lungs, irreversibly destroying normal lung architecture and hindering a person's ability to breathe.

The Charter will see, for the first time, patient advocacy groups and healthcare professionals come together at a European level to campaign for more standardized care and equal access to diagnosis, treatment and after care options for those with IPF in Europe.

Advocacy groups and healthcare professionals from a number of European countries will meet in Brussels on March 8 this year to identify and agree the key priorities for IPF patients. The Charter will then form a central part of efforts to raise awareness of these issues and to bring them to the attention of national and European policy makers.  

The Charter will be launched via an online public petition and a lunch event at the EU Parliament later this year.  

Commenting on the initiative, Cristina Coteanu, the lead candidate for the Fédéralistes Démocrates Francophones in Belgium and a key supporter of the initiative, said:

"Despite its devastating impact on patients, IPF has not received the attention it deserves in Europe. This initiative is an important step forward in raising awareness of the condition and for galvanizing national and European policy makers into taking action to address inequalities in care and treatment. I look forward to supporting the Charter when it has been developed, and to securing the backing of colleagues from across the political spectrum."

Lida Naber of the Dutch Pulmonary Fibrosis Society (Longfibrose NL) added:

"We strongly believe that all pulmonary fibrosis patients throughout Europe should receive the best available treatment and support, alongside appropriate reimbursement. It is important for the IPF community to speak with one voice and we are looking forward to campaigning with our colleagues to push treatment and care up the agenda and to address unacceptable inequalities in care."

Giacomo di Nepi, General Manager of InterMune Europe stated:

"InterMune is dedicated to IPF research and the development of treatments for this irreversible disease. We are pleased to play our part in supporting the Charter initiative, which will be essential for improving care and access to healthcare services. The development of a Charter provides clinicians, patient advocacy groups and patients the opportunity of working together to identify the key concerns that can and must be addressed by policy makers."

InterMune is proud to support European patient associations in their commitment to develop an IPF Charter that will benefit IPF patients.  InterMune has contributed financially to the organization of the first meeting in Brussels.

About IPF

IPF is an irreversible, progressive and ultimately fatal fibrotic interstitial lung disease which inevitably leads to worsening lung function and exercise tolerance, and shortness of breath.  Every IPF patient follows a different and unpredictable course and it is not possible to predict if a patient will progress slowly or rapidly, or when the rate of decline may change.  Periods of transient clinical stability in IPF, should they occur, inevitably give way to continued disease progression.  The median survival time from diagnosis is two to five years,[i],[ii]with a five-year survival rate of approximately 20-40 percent [i],[ii] which makes IPF more rapidly lethal than many cancers, including breast, ovarian and colorectal [iii],[iv].  IPF typically occurs in patients over the age of 45, and is more common in men than in women.[iii]

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is marketed by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Notes to Editors

For further information, please contact:

  • Owen Bethell, Senior Account Director, Weber Shandwick, +41(0)22-879-85-11 [email protected]
  • Manuela Maronati, Senior Vice President Sales, Marketing and Advocacy, Europe, InterMune International AG, +41-61-466-80-41 / [email protected]

i. American Thoracic Society/European Respiratory Society. Am J Respir Crit Care Med 2002;165:277(304.

ii. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP: Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 157: 199-203.

iii. Raghu G et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-16.

Raghu G et al. Am J Respir Crit Care Med 2011;183:788(824

iv. Cancer Facts and Figures 2009, American Cancer Society. PAH data source: Hamilton, N. and Elliot C. 13.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...
An edge gateway is an essential piece of infrastructure for large scale cloud-based services. In his session at 17th Cloud Expo, Mikey Cohen, Manager, Edge Gateway at Netflix, detailed the purpose, benefits and use cases for an edge gateway to provide security, traffic management and cloud cross region resiliency. He discussed how a gateway can be used to enhance continuous deployment and help testing of new service versions and get service insights and more. Philosophical and architectural ap...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities - ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups.
DXWorldEXPO LLC announced today that Telecom Reseller has been named "Media Sponsor" of CloudEXPO | DXWorldEXPO 2018 New York, which will take place on November 11-13, 2018 in New York City, NY. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
By 2021, 500 million sensors are set to be deployed worldwide, nearly 40x as many as exist today. In order to scale fast and keep pace with industry growth, the team at Unacast turned to the public cloud to build the world's largest location data platform with optimal scalability, minimal DevOps, and maximum flexibility. Drawing from his experience with the Google Cloud Platform, VP of Engineering Andreas Heim will speak to the architecture of Unacast's platform and developer-focused processes.
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, will provide an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life ...
"I think DevOps is now a rambunctious teenager – it’s starting to get a mind of its own, wanting to get its own things but it still needs some adult supervision," explained Thomas Hooker, VP of marketing at CollabNet, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We are still a relatively small software house and we are focusing on certain industries like FinTech, med tech, energy and utilities. We help our customers with their digital transformation," noted Piotr Stawinski, Founder and CEO of EARP Integration, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Chris Matthieu is the President & CEO of Computes, inc. He brings 30 years of experience in development and launches of disruptive technologies to create new market opportunities as well as enhance enterprise product portfolios with emerging technologies. His most recent venture was Octoblu, a cross-protocol Internet of Things (IoT) mesh network platform, acquired by Citrix. Prior to co-founding Octoblu, Chris was founder of Nodester, an open-source Node.JS PaaS which was acquired by AppFog and ...
The Founder of NostaLab and a member of the Google Health Advisory Board, John is a unique combination of strategic thinker, marketer and entrepreneur. His career was built on the "science of advertising" combining strategy, creativity and marketing for industry-leading results. Combined with his ability to communicate complicated scientific concepts in a way that consumers and scientists alike can appreciate, John is a sought-after speaker for conferences on the forefront of healthcare science,...
"We focus on SAP workloads because they are among the most powerful but somewhat challenging workloads out there to take into public cloud," explained Swen Conrad, CEO of Ocean9, Inc., in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"The Striim platform is a full end-to-end streaming integration and analytics platform that is middleware that covers a lot of different use cases," explained Steve Wilkes, Founder and CTO at Striim, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...